Literature DB >> 14990602

Prevalence and relevance of EBV latency in nasopharyngeal carcinoma in Israel.

G Bar-Sela1, A Kuten, I Minkov, E Gov-Ari, O Ben-Izhak.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) is frequently associated with Epstein-Barr virus (EBV). The incidence of NPC in Western countries is lower than in the Far East, and EBV latency in NPC is less prevalent. Israel, as a part of the Mediterranean area, is one of the countries with an intermediate risk for NPC.
METHODS: Immunohistochemistry (IHC) for latent membrane protein 1 (LMP-1) and in situ hybridisation (ISH) for EBV encoded RNA (EBER) were used to evaluate the prevalence and possible prognostic value of EBV latency among Israeli patients with NPC. Forty five patients with different NPC histologies were studied.
RESULTS: LMP-1 IHC was positive in six samples only, all with undifferentiated histology. EBER ISH was positive in 40 of the 45 samples. According to histological type, three of five patients with squamous cell carcinoma were EBV positive and 37 of 40 non-keratinising and undifferentiated carcinoma cases were positive. Although EBV was more prevalent in patients with non-squamous carcinoma, the difference was not significant, probably because of the small number of patients with keratinising carcinoma. With regard to the clinical categories and survival, no significant difference could be detected between patients who were positive or negative for EBER ISH. No association was found between EBV latency and patient sex, age, origin, stage, or survival.
CONCLUSIONS: NPC in Israel is highly associated with EBV latency as detected by EBER ISH. LMP-1 IHC is considerably less sensitive in detecting EBV latency in NPC among the same patient group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990602      PMCID: PMC1770229          DOI: 10.1136/jcp.2003.013094

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  Computed tomography in nasopharyngeal carcinoma: Part I: T-stage conversion with CT-staging.

Authors:  P Olmi; E Cellai; A Chiavacci; C Fallai; G Giannardi; R Fargnoli; N Villari
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-11       Impact factor: 7.038

2.  Nasopharyngeal carcinoma in Israel: epidemiology and Epstein-Barr virus-related serology.

Authors:  S Bogger-Goren; T Gotlieb-Stematsky; M Rachima; E Barkowsky; J Schlomo-David
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

3.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

4.  Expression of Epstein-Barr virus-encoded RNA and biological markers in Italian nasopharingeal carcinomas.

Authors:  E Gabusi; C Lattes; M Fiorentino; A D'Errico; W F Grigioni
Journal:  J Exp Clin Cancer Res       Date:  2001-09

5.  Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches.

Authors:  M Rahima; E Rakowsky; J Barzilay; J Sidi
Journal:  Cancer       Date:  1986-08-15       Impact factor: 6.860

6.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

Review 7.  Nasopharyngeal cancer: epidemiology, staging, and treatment.

Authors:  A Fandi; M Altun; N Azli; J P Armand; E Cvitkovic
Journal:  Semin Oncol       Date:  1994-06       Impact factor: 4.929

8.  Update on nasopharyngeal carcinoma in northern Israel.

Authors:  A Kuten; Y Cohen; R Lavie; J Dale; M B Ben Arush; H Goldberg; M Stein
Journal:  Strahlenther Onkol       Date:  1994-10       Impact factor: 3.621

9.  Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma.

Authors:  Y S Zong; J S Sham; M H Ng; X T Ou; Y Q Guo; S A Zheng; J S Liang; H Qiu
Journal:  Cancer       Date:  1992-01-01       Impact factor: 6.860

10.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma.

Authors:  L S Young; C W Dawson; D Clark; H Rupani; P Busson; T Tursz; A Johnson; A B Rickinson
Journal:  J Gen Virol       Date:  1988-05       Impact factor: 3.891

View more
  13 in total

1.  Nasopharyngeal carcinoma in a south European population: epidemiological data and clinical aspects in Portugal.

Authors:  Breda Eduardo; Catarino Raquel; Medeiros Rui
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-08       Impact factor: 2.503

Review 2.  Update in pediatric nasopharyngeal undifferentiated carcinoma.

Authors:  Line Claude; Emmanuel Jouglar; Loig Duverge; Daniel Orbach
Journal:  Br J Radiol       Date:  2019-07-31       Impact factor: 3.039

3.  CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma.

Authors:  Meir Shamay; Jennifer A Kanakry; John S W Low; Netanel A Horowitz; Guy Journo; Anuj Ahuja; Yonatan Eran; Elinor Barzilai; Eldad J Dann; Jennifer Stone; Wan Lu Woo; Wen-Son Hsieh; Rena R Xian; Richard F Ambinder
Journal:  Blood Adv       Date:  2020-04-28

4.  The incidence of Epstein-Barr virus in nasopharyngeal carcinoma of Jordanian patients.

Authors:  Ismail Matalka; Mohammad Al Hamad; Maysa Al-Hussaini; Firas Q Alzoubi
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-16       Impact factor: 2.503

5.  Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.

Authors:  K-B Tan; T C Putti
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

6.  Expression of Epstein-Barr-virus-encoded small nuclear RNA in nasopharyngeal carcinomas of Aegean Turkish patients.

Authors:  Yeşim Ertan; Mine Hekimgil; Serap Karaarslan; Saliha Soydan
Journal:  Virchows Arch       Date:  2008-02-26       Impact factor: 4.064

7.  Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.

Authors:  J S Kalpoe; P B Douwes Dekker; J H J M van Krieken; R J Baatenburg de Jong; A C M Kroes
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

8.  Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients.

Authors:  Yan-Xin Ren; Jie Yang; Li-Juan Zhang; Rui-Mei Sun; Liu-Fang Zhao; Ming Zhang; Yun Chen; Jing Ma; Kun Qiao; Qiang-Ming Sun; Hai-Ting Long; Yun-Chao Huang; Xiao-Jiang Li
Journal:  Mol Clin Oncol       Date:  2013-09-26

9.  Brain metastasis of nasopharyngeal carcinoma: a case report and literature review.

Authors:  Orit Kaidar-Person; Jonathan Kuten; Fadi Atrash; Salem Billan; Abraham Kuten
Journal:  Case Rep Med       Date:  2012-02-20

10.  Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering.

Authors:  Yanping Chen; Xiongwei Zheng; Gang Chen; Chen He; Weifeng Zhu; Shangyuan Feng; Gangqin Xi; Rong Chen; Fenghua Lan; Haishan Zeng
Journal:  Int J Nanomedicine       Date:  2011-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.